{"id":"W4412479885","doi":"10.1016/j.annonc.2025.05.048","title":"36P BREAKWATER: Post-hoc subgroup efficacy analyses by chemotherapy ± bevacizumab regimens vs encorafenib plus cetuximab + mFOLFOX6","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada); Sunnybrook Health Science Centre","funders":"Cilag; MSD K.K.; Chugai Pharmaceutical; EMD Serono; Nordic Pharma Group; Novocure; Menarini Group; American Association for Cancer Research; Incyte; Servier; Pfizer Japan; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; European Society for Medical Oncology; Astellas Pharma; Eisai; Miyarisan Pharmaceutical; Daiichi-Sankyo; AstraZeneca; Genentech; University of Oxford; Sirtex Medical; Cancer Research UK; Springworks Therapeutics; Seagen; Sysmex Corporation; BeiGene; Mirati Therapeutics; Takeda Pharmaceutical Company; Ono Pharmaceutical; Eli Lilly and Company; Les Laboratories Pierre Fabre; Pfizer; Taiho Pharmaceutical; Boehringer Ingelheim Japan; Merck KGaA; Natera; Regeneron Pharmaceuticals; Ipsen; Array BioPharma; Amgen; Bristol-Myers Squibb; American Society of Clinical Oncology; Revolution Medicines; Exelixis; Sanofi; Celgene","keywords":"Medicine; Bevacizumab; Cetuximab; Oncology; Post-hoc analysis; Internal medicine; Chemotherapy; Post hoc; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01311633,0.005517547,0.01394626,0.001386533,0.001059948,0.002829266,0.003608152,0.004880801,0.04011015],"category_scores_gemma":[0.02296456,0.001985187,0.02447637,0.001331169,0.001673031,0.00651393,0.002245602,0.01496434,0.003582127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00364331,"about_ca_system_score_gemma":0.005292599,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005488757,"about_ca_topic_score_gemma":0.0110059,"domain_scores_codex":[0.9816535,0.008770893,0.001241492,0.002987157,0.001231977,0.004114987],"domain_scores_gemma":[0.9871435,0.007838713,0.00122139,0.001752958,0.0008543865,0.001189198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9307256,0.002819204,0.001812264,0.001460858,0.02847544,0.0002357017,0.0001575805,0.001535526,0.002820284,0.0005516714,0.01504505,0.01436092],"study_design_scores_gemma":[0.5549055,0.2130443,0.0693918,0.0009613555,0.08071224,0.0003061655,0.001075529,0.01971186,0.01315291,0.008262414,0.03790092,0.000575033],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8442621,0.01434758,0.01516643,0.009777502,0.02488793,0.01619557,0.04802397,0.001974966,0.02536402],"genre_scores_gemma":[0.887232,0.002213924,0.01279785,0.009788083,0.002383085,0.01924584,0.01019234,0.00101546,0.05513144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04011015,"threshold_uncertainty_score":0.1341818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08269816231793721,"score_gpt":0.4674271892517783,"score_spread":0.3847290269338411,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}